Cargando…
Resveratrol inhibits nonalcoholic fatty liver disease in rats
BACKGROUND: The prevalence of nonalcoholic fatty liver disease (NAFLD) is high. NAFLD is linked to obesity, diabetes mellitus, and hypertriglyceridemia. Approximately 20% of patients with NAFLD will eventually develop cirrhosis. Our purpose was to investigate whether resveratrol decreased hepatic st...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2547101/ https://www.ncbi.nlm.nih.gov/pubmed/18782455 http://dx.doi.org/10.1186/1471-230X-8-40 |
_version_ | 1782159210315776000 |
---|---|
author | Bujanda, Luis Hijona, Elizabeth Larzabal, Mikel Beraza, Marta Aldazabal, Pablo García-Urkia, Nerea Sarasqueta, Cristina Cosme, Angel Irastorza, Belen González, Alberto Arenas, Juan I |
author_facet | Bujanda, Luis Hijona, Elizabeth Larzabal, Mikel Beraza, Marta Aldazabal, Pablo García-Urkia, Nerea Sarasqueta, Cristina Cosme, Angel Irastorza, Belen González, Alberto Arenas, Juan I |
author_sort | Bujanda, Luis |
collection | PubMed |
description | BACKGROUND: The prevalence of nonalcoholic fatty liver disease (NAFLD) is high. NAFLD is linked to obesity, diabetes mellitus, and hypertriglyceridemia. Approximately 20% of patients with NAFLD will eventually develop cirrhosis. Our purpose was to investigate whether resveratrol decreased hepatic steatosis in an animal model of steatosis, and whether this therapeutic approach resulted in a decrease in tumor necrosis factor α (TNF-α) production, lipid peroxidation and oxidative stress. METHODS: Male Wistar CRL: Wi (Han) (225 g) rats were randomized into three groups. A control group (n = 12) was given free access to regular dry rat chow for 4 weeks. The steatosis (n = 12) and resveratrol (n = 12) groups were given free access to feed (a high carbohydrate-fat free modified diet) and water 4 days per week, and fasted for the remaining 3 days for 4 weeks. Rats in the resveratrol group were given resveratrol 10 mg daily by the oral route. All rats were killed at 4 weeks and assessed for fatty infiltration and bacterial translocation. Levels of TNF-α in serum, hepatic malondialdehyde (MDA), oxidative stress (superoxide dismutase, glutathione peroxidase, catalase and nitric oxide synthase) and biochemical parameters were measured. RESULTS: Fat deposition was decreased in the resveratrol group as compared to the steatosis group (Grade 1 vs Grade 3, P < 0.05). TNF-α and MDA levels were significantly increased in the steatosis group (TNF-α; 33.4 ± 5.2 vs 26.24 ± 3.47 pg/ml and MDA; 9.08 ± 0.8 vs 3.17 ± 1.45 μM respectively, P < 0.05). This was accompanied by increased superoxide dismutase, glutathione peroxidase and catalase and decreased nitric oxide synthase in the liver of resveratrol group significantly (P < 0.05 vs steatosis group). Bacterial translocation was not found in any of the groups. Glucose levels were decreased in the group of rats given resveratrol (P < 0.05). CONCLUSION: Resveratrol decreased NAFLD severity in rats. This effect was mediated, at least in part, by TNF-α inhibition and antioxidant activities. |
format | Text |
id | pubmed-2547101 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-25471012008-09-23 Resveratrol inhibits nonalcoholic fatty liver disease in rats Bujanda, Luis Hijona, Elizabeth Larzabal, Mikel Beraza, Marta Aldazabal, Pablo García-Urkia, Nerea Sarasqueta, Cristina Cosme, Angel Irastorza, Belen González, Alberto Arenas, Juan I BMC Gastroenterol Research Article BACKGROUND: The prevalence of nonalcoholic fatty liver disease (NAFLD) is high. NAFLD is linked to obesity, diabetes mellitus, and hypertriglyceridemia. Approximately 20% of patients with NAFLD will eventually develop cirrhosis. Our purpose was to investigate whether resveratrol decreased hepatic steatosis in an animal model of steatosis, and whether this therapeutic approach resulted in a decrease in tumor necrosis factor α (TNF-α) production, lipid peroxidation and oxidative stress. METHODS: Male Wistar CRL: Wi (Han) (225 g) rats were randomized into three groups. A control group (n = 12) was given free access to regular dry rat chow for 4 weeks. The steatosis (n = 12) and resveratrol (n = 12) groups were given free access to feed (a high carbohydrate-fat free modified diet) and water 4 days per week, and fasted for the remaining 3 days for 4 weeks. Rats in the resveratrol group were given resveratrol 10 mg daily by the oral route. All rats were killed at 4 weeks and assessed for fatty infiltration and bacterial translocation. Levels of TNF-α in serum, hepatic malondialdehyde (MDA), oxidative stress (superoxide dismutase, glutathione peroxidase, catalase and nitric oxide synthase) and biochemical parameters were measured. RESULTS: Fat deposition was decreased in the resveratrol group as compared to the steatosis group (Grade 1 vs Grade 3, P < 0.05). TNF-α and MDA levels were significantly increased in the steatosis group (TNF-α; 33.4 ± 5.2 vs 26.24 ± 3.47 pg/ml and MDA; 9.08 ± 0.8 vs 3.17 ± 1.45 μM respectively, P < 0.05). This was accompanied by increased superoxide dismutase, glutathione peroxidase and catalase and decreased nitric oxide synthase in the liver of resveratrol group significantly (P < 0.05 vs steatosis group). Bacterial translocation was not found in any of the groups. Glucose levels were decreased in the group of rats given resveratrol (P < 0.05). CONCLUSION: Resveratrol decreased NAFLD severity in rats. This effect was mediated, at least in part, by TNF-α inhibition and antioxidant activities. BioMed Central 2008-09-09 /pmc/articles/PMC2547101/ /pubmed/18782455 http://dx.doi.org/10.1186/1471-230X-8-40 Text en Copyright © 2008 Bujanda et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Bujanda, Luis Hijona, Elizabeth Larzabal, Mikel Beraza, Marta Aldazabal, Pablo García-Urkia, Nerea Sarasqueta, Cristina Cosme, Angel Irastorza, Belen González, Alberto Arenas, Juan I Resveratrol inhibits nonalcoholic fatty liver disease in rats |
title | Resveratrol inhibits nonalcoholic fatty liver disease in rats |
title_full | Resveratrol inhibits nonalcoholic fatty liver disease in rats |
title_fullStr | Resveratrol inhibits nonalcoholic fatty liver disease in rats |
title_full_unstemmed | Resveratrol inhibits nonalcoholic fatty liver disease in rats |
title_short | Resveratrol inhibits nonalcoholic fatty liver disease in rats |
title_sort | resveratrol inhibits nonalcoholic fatty liver disease in rats |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2547101/ https://www.ncbi.nlm.nih.gov/pubmed/18782455 http://dx.doi.org/10.1186/1471-230X-8-40 |
work_keys_str_mv | AT bujandaluis resveratrolinhibitsnonalcoholicfattyliverdiseaseinrats AT hijonaelizabeth resveratrolinhibitsnonalcoholicfattyliverdiseaseinrats AT larzabalmikel resveratrolinhibitsnonalcoholicfattyliverdiseaseinrats AT berazamarta resveratrolinhibitsnonalcoholicfattyliverdiseaseinrats AT aldazabalpablo resveratrolinhibitsnonalcoholicfattyliverdiseaseinrats AT garciaurkianerea resveratrolinhibitsnonalcoholicfattyliverdiseaseinrats AT sarasquetacristina resveratrolinhibitsnonalcoholicfattyliverdiseaseinrats AT cosmeangel resveratrolinhibitsnonalcoholicfattyliverdiseaseinrats AT irastorzabelen resveratrolinhibitsnonalcoholicfattyliverdiseaseinrats AT gonzalezalberto resveratrolinhibitsnonalcoholicfattyliverdiseaseinrats AT arenasjuani resveratrolinhibitsnonalcoholicfattyliverdiseaseinrats |